Astellas Pharma Inc. (4503.T) Stock
Healthcare · Drug Manufacturers - General · Member of Nikkei 225
Astellas Pharma Inc. (4503.T) closed at JPY 2,356.50 on 2026-10-15, a change of +54.5 % over the past year, with a market capitalization of JPY 4.35T.
Astellas Pharma Inc. recent closing prices
| Date | Close (JPY) |
|---|---|
| 2026-10-15 | 2,356.50 |
| 2026-10-14 | 2,262.50 |
| 2026-10-13 | 2,300.50 |
| 2026-10-12 | 2,300.50 |
| 2026-10-09 | 2,247.50 |
| 2026-10-08 | 2,248.00 |
| 2026-10-07 | 2,255.50 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Astellas Pharma Inc. key figures
- Previous close
- JPY 2,356.50 (2026-10-15)
- 1-year change
- +54.5 %
- Market cap
- JPY 4.35T
- Enterprise value
- JPY 4.57T
- P/E ratio (trailing)
- 11.48
- P/E ratio (forward)
- 32.04
- EPS (trailing)
- 211.51
- EPS (forward)
- 75.77
- PEG ratio
- 0.37
- Price to book
- 2.24
- Revenue growth
- 26.7 %
- Earnings growth
- 107.2 %
- Dividend per share (trailing)
- 78.00
- Short ratio
- n/a
- Employees
- 14,099
- Analyst consensus (third-party)
- buy
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Astellas Pharma Inc.
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Astellas Pharma Inc. and compare it with other stocks.
Analyze 4503.TAll Nikkei 225 stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Astellas Pharma Inc. shares.